Therefore, understanding the effect of HDAC8 on resistance to ccRCC‐targeted therapies and elucidating the underlying mechanisms are critical for identifying potential therapeutic targets for ccRCC. This evidence concerns the gene HDAC8 and nonpapillary renal cell carcinoma.